An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

J. Larkin, M.P. Brown, A.M. Arance, A. Hauschild, P. Queirolo, M.D. Vecchio, P.A. Ascierto, I. Krajsová, J. Schachter, B. Neyns, C. Garbe, V.C. Sileni, M. Mandalà, H. Gogas, E. Espinosa, G. Hospers, P. Lorigan, M. Nyakas, A. Guminski, G. LiszkayP. Rutkowski, W. Miller, M. Donica, M. Makrutzki, C. Blank

Research output: Contribution to journalArticlepeer-review

Cite this